Pre-clinical assessment of Roflumilast therapy in a thoracic model of spinal cord injury

• Published in: Pharmaceutics Vol. 15; no. 5; pp. 1 - 18
• Main Authors: Sousa, Carla S., Lima, Rui Augusto Ribeiro, Cibrão, Jorge R., Gomes, Eduardo D., Fernandes, Luís S., Pinho, Tiffany Santos, Silva, Deolinda, Campos, Jonas Oliveira, Salgado, António J., Silva, Nuno André Martins
• Format: Journal Article
• Language: English
• Published: Switzerland Multidisciplinary Digital Publishing Institute 21.05.2023; MDPI AG; MDPI
• Subjects: Animals; Chronic obstructive pulmonary disease; Cyclic adenylic acid; Drug approval; Ethylenediaminetetraacetic acid; Glycoproteins; Health aspects; Kinases; Medical research; Medicine, Experimental; Motor recovery; Neurosciences; Proteins; Rat model; Roflumilast; Spinal cord injuries; Spinal cord injury; Vascular endothelial growth factor; spinal cord injury; rat model; Roflumilast; motor recovery
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15051556

The failure of axons to regenerate after a spinal cord injury (SCI) remains one of the greatest challenges in neuroscience. The initial mechanical trauma is followed by a secondary injury cascade, creating a hostile microenvironment, which not only is not permissive to regeneration but also leads to further damage. One of the most promising approaches for promoting axonal regeneration is to maintain the levels of cyclic adenosine monophosphate (cAMP), specifically by a phosphodiesterase-4 (PDE4) inhibitor expressed in neural tissues. Therefore, in our study, we evaluated the therapeutic effect of an FDA-approved PDE4 inhibitor, Roflumilast (Rof), in a thoracic contusion rat model. Results indicate that the treatment was effective in promoting functional recovery. Rof-treated animals showed improvements in both gross and fine motor function. Eight weeks post-injury, the animals significantly recovered by achieving occasional weight-supported plantar steps. Histological assessment revealed a significant decrease in cavity size, less reactive microglia, as well as higher axonal regeneration in treated animals. Molecular analysis revealed that IL-10 and IL-13 levels, as well as VEGF, were increased in the serum of Rof-treated animals. Overall, Roflumilast promotes functional recovery and supports neuroregeneration in a severe thoracic contusion injury model and may be important in SCI treatment. This research was supported by Prémios Santa Casa Neurociências—Prize Melo e Castro for Spinal Cord Injury Research (MC-18-2021) and by national funds, through the Foundation for Science and Technology (FCT)—project PTDC/MED-FAR/29751/2017, project UIDB/50026/2020 and UIDP/50026/2020. We would like to acknowledge the financial support by the Foundation for Science and Technology to the following authors: RL (PD/BDE/127836/2016), JRC (SFRH/BD/145860/2019) and NAS (CEECIND/04794/2007). We would like to acknowledge the support of the ICVS Scien tific Microscopy Platform, members of the national infrastructure PPBI—Portuguese Platform of Bioimaging (PPBI-POCI-01-0145-FEDER-022122).